Early research (Phase 1)Ended earlyNCT03429101What this trial is testingPoziotinib in Combination With T-DM1 in HER2-Positive Breast CancerWho this might be right forBreast Cancer Spectrum Pharmaceuticals, Inc 6
Testing effectiveness (Phase 2)Study completedNCT00934856What this trial is testingTrastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 98
Large-scale testing (Phase 3)Ended earlyNCT01641939What this trial is testingTrastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerWho this might be right forGastric Cancer Hoffmann-La Roche 415
Large-scale testing (Phase 3)Study completedNCT03084939What this trial is testingEfficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 351
Early research (Phase 1)Study completedNCT03032107What this trial is testingPembrolizumab In Combination With Trastuzumab-DM1Who this might be right forBreast Cancer Dana-Farber Cancer Institute 20
Large-scale testing (Phase 3)Study completedNCT01702571What this trial is testingTrastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentWho this might be right forBreast Cancer Hoffmann-La Roche 2,185
Testing effectiveness (Phase 2)Ended earlyNCT03784599What this trial is testingT-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCWho this might be right forCarcinoma, Non-Small-Cell Lung The Netherlands Cancer Institute 28
Not applicableUnknownNCT05231863What this trial is testingTyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world StudyWho this might be right forBreast Cancer The First Affiliated Hospital with Nanjing Medical University 100
Testing effectiveness (Phase 2)Ended earlyNCT02658084What this trial is testingVinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast CancerWho this might be right forBreast CancerMetastatic Breast Cancer University of Miami 2
Testing effectiveness (Phase 2)Study completedNCT02289833What this trial is testingTrastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Who this might be right forNon-Small Cell Lung Cancer Hoffmann-La Roche 49
Large-scale testing (Phase 3)Looking for participantsNCT07008976What this trial is testingClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast CancerWho this might be right forMetastatic Breast Cancer Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 246
Testing effectiveness (Phase 2)Active Not RecruitingNCT02326974What this trial is testingT-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCAWho this might be right forHER-2 Positive Breast CancerBreast CancerStage II Breast Cancer+1 more Dana-Farber Cancer Institute 164
Testing effectiveness (Phase 2)WithdrawnNCT03203616What this trial is testingKadcyla In pAtients With bRAin MetastasisWho this might be right forMetastatic HER2-positive Breast Cancer With Brain Metastasis Jules Bordet Institute
Testing effectiveness (Phase 2)Ended earlyNCT03709082What this trial is testingPalbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerWho this might be right forHER2-positive Breast CancerBreast Cancer Metastatic University of Kansas Medical Center 3
Not applicableLooking for participantsNCT06928818What this trial is testingTrastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in KoreaWho this might be right forCancer of BreastTrastuzumab EmtansineTrastuzumab Deruxtecan Seoul National University Hospital 100
Early research (Phase 1)Active Not RecruitingNCT05650879What this trial is testingELVN-002 in HER2 Mutant Non-Small Cell Lung CancerWho this might be right forHER2 Mutant Non-small Cell Lung CancerHER2-positive Metastatic Breast CancerHER2 Gene Mutation+1 more Enliven Therapeutics 198
Large-scale testing (Phase 3)Active Not RecruitingNCT04457596What this trial is testingT-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialWho this might be right forAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2 Positive Breast Carcinoma+4 more Alliance for Clinical Trials in Oncology 1,056
Testing effectiveness (Phase 2)UnknownNCT04158947What this trial is testingHER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 AloneWho this might be right forHER2-positive Breast CancerBrain Metastases xuexin he 130
Large-scale testing (Phase 3)Active Not RecruitingNCT06316531What this trial is testingA Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerWho this might be right forHER2-positive Breast Cancer Sichuan Baili Pharmaceutical Co., Ltd. 274
Early research (Phase 1)Study completedNCT03153163What this trial is testingStudy of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast CancerWho this might be right forBreast Neoplasms Hoffmann-La Roche 11